Global Expansion Across China, U.S. and Europe: China’s Fully Magnetically Levitated Artificial Heart Goes Global

BrioHealth Solutions has hit a landmark milestone in its worldwide commercial rollout.

The company’s self-engineered fully magnetically levitated implantable ventricular assist device BrioVAD is under evaluation in the pan-European BRIOLIFE clinical trial. After winning Dutch regulatory clearance in May, the program obtained separate clinical approvals from Austrian and German authorities in June, speeding multi-center study deployment throughout Europe. All nine initial participating European sites have finished investigator training, and surgeons completed the continent’s first BrioVAD implant in early June in the Netherlands.

This milestone distinguishes BrioHealth Solutions as China’s sole ventricular assist device maker with coordinated clinical programs covering China, the U.S. and Europe—a defining breakthrough for Chinese high-end medical devices expanding overseas.

The company’s swift regulatory progress in Europe stands out in the medtech sector. It took just six months from the launch of European clinical filings to secure three national trial authorizations, underscoring the speed at which China’s innovative device firms can navigate Western regulatory systems. This streamlined review process rests on a standardized clinical assessment platform built years in advance to mirror U.S. and EU compliance criteria. BrioHealth Solutions continues to scale its global footprint by leaning on proprietary technology, an integrated clinical data matrix and localized overseas operating teams.

Heart failure remains one of the world’s most intractable cardiovascular illnesses. Per 2021 advanced heart failure referral guidance published by the American Heart Association (AHA), more than 60 million people globally live with heart failure, and roughly 5% progress to end-stage disease each year. Europe alone counts over 10 million prevalent heart failure patients, with case numbers climbing steadily. Conventional drugs and legacy medical devices deliver limited benefits for late-stage sufferers, leaving left ventricular assist devices (LVADs) as the primary widely adopted therapy to extend patient survival.

This vast patient population creates substantial commercial potential for end-stage heart failure care. Europe hosts the world’s most established LVAD market, yet the segment has operated as a near-monopoly for one international manufacturer. The launch of BrioHealth Solutions’ BRIOLIFE trial upends this long-standing market structure, marking the formal entry of a Chinese-developed LVAD into mainstream European clinical practice.

Managed by BrioHealth BV, BrioHealth Solutions’ fully owned European subsidiary, BRIOLIFE is a prospective, multi-center, single-arm objective performance criterion non-inferiority trial. The program will partner with 12 leading European cardiac centers to enroll approximately 60 adult patients with end-stage heart failure, covering both short-term and long-term treatment scenarios. Its primary efficacy endpoint measures patient survival six months after implantation.

BrioHealth Solutions’ European regulatory submissions demonstrate notable execution speed. The company filed clinical registration packages in Austria and Germany in November and December 2025, respectively, earning both approvals in June 2026. Its Dutch application cleared review this May, with the first implantation completed less than a month later.

The EU’s updated Medical Device Regulation (MDR) imposes strict clinical approval barriers for high-risk implantable devices. Individual European nations enforce independent regulatory standards paired with lengthy ethics reviews, creating prolonged validation timelines for new entrants. BrioHealth Solutions’ ability to clear simultaneous clinical and regulatory hurdles across the Netherlands, Germany and Austria in such a condensed window represents an unprecedented milestone in the global expansion track record of China’s high-risk active implantable medical devices.

German clinical authorization carries outsized strategic importance for BrioHealth Solutions. Germany operates Europe’s largest LVAD market, supported by sophisticated clinical infrastructure and rigorous research benchmarks. It serves as the continent’s benchmark for artificial heart clinical trials, commercialization and regulatory oversight. Securing German trial access hands BrioHealth Solutions critical entry into Europe’s core advanced heart failure treatment market.

Parallel to the three national regulatory greenlights, investigator training wrapped at nine elite European cardiac centers tapped for the initial trial phase. The roster includes Medizinische Universität Wien, DHZC (German Heart Center Berlin Charité), Helios Heart Center Leipzig and UMC Utrecht. These institutions represent the highest tier of European cardiovascular surgery: many lead the drafting of international clinical guidelines and coordinate large cross-border multi-center trials, consistently logging the region’s highest annual implantation volumes. Early widespread buy-in from top-tier centers signals broad enthusiasm among European clinicians to break the existing market monopoly and adopt a novel fully magnetically levitated technology alternative.

No single technical advantage enabled BrioHealth Solutions to secure synchronized trial approvals across the Netherlands, Germany and Austria. Its fast European rollout stems from aligned progress across three core pillars: differentiated proprietary hardware technology, comprehensive cross-border clinical evidence datasets, and strong execution from embedded local professional teams.

On the engineering front, BrioHealth Solutions’ artificial heart relies on its in-house fully magnetically levitated rotor architecture. The friction-free rotor minimizes blood shear stress, cutting incidences of hemolysis, pump thrombosis and other adverse events to mitigate long-term complication risks at the design stage. Beyond this, the pump features a smaller, lighter and slimmer profile than competing international models. Its proprietary flexible cable—the thinnest of its class worldwide at only 3.3 millimeters in diameter—sharply lowers risks of percutaneous exit-site infection, delivering infection rates at the lower end of global published datasets and improving long-term quality of life for implanted patients.

Clinically, globalization sits at the core of BrioHealth Solutions’ development strategy. The firm has built a complete cross-regional evidence library combining long-term real-world follow-up data from China, a large randomized controlled trial underway in the U.S., and its ongoing prospective European study.

Domestically, over 800 commercial CH-VAD implantations have generated an extensive long-term real-world patient dataset. All clinical evaluations adhere strictly to FDA statistical standards, tracking patient survival alongside sustained long-term device safety metrics.

Two-year domestic multi-center follow-up data demonstrates that CH-VAD achieves superior survival outcomes compared with competing devices, alongside marked reductions in critical long-term safety endpoints. The incidence of ischemic stroke, pump thrombosis and gastrointestinal bleeding decreased significantly relative to established industry benchmarks.

Varied patient follow-up durations make raw percentage figures an unreliable benchmark for adverse event risk. Under global standardized clinical protocols, the industry uses Events Per Patient Year (EPPY) as the core metric to measure long-term safety for implantable devices.

BrioHealth Solutions is China’s only VAD developer to maintain systematic long-term regulatory monitoring, full adverse event documentation and standardized EPPY-based reporting. This robust, complete real-world evidence foundation paved the way for its U.S. FDA Premarket Approval (PMA) clinical clearance and drastically accelerated European trial review timelines.

In the U.S., BrioHealth Solutions launched its INNOVATE trial in late 2024. The large-scale prospective randomized head-to-head study directly benchmarks BrioVAD against Abbott’s HeartMate 3 across 60 top U.S. implantation centers. Researchers have completed more than 200 implantations to date. Data generated from the U.S. trial will be combined with BRIOLIFE European outcomes for integrated analysis, forming the core clinical dossier supporting BrioVAD’s EU CE marking application.

This dual-evidence clinical approach differs from the industry standard of relying solely on single-region data for EU certification, enabling fuller, more quantitative and rigorous evaluation of product safety risks.

Localized U.S. and European operating teams form another critical driver of streamlined clinical progress. BrioHealth Solutions launched its U.S. subsidiary at founding to exclusively manage American clinical programs, while all European trial operations fall under BrioHealth BV’s full oversight. Teams hire local clinical, regulatory and medical specialists deeply familiar with U.S. and EU rulebooks, individual site surgical workflows and regional Good Clinical Practice (GCP) standards. Local staff oversee end-to-end trial delivery: protocol adaptation, cross-border ethics submissions, clinical site negotiations, regional reimbursement advocacy and first implantation launches. This ground-level localized management slashes cross-national regulatory timelines and turns broad global clinical roadmaps into actionable execution.

Securing clinical trial clearance in three European nations marks far more than an internal corporate milestone for BrioHealth Solutions. It signals a new era for China’s high-end medical device global expansion. Chinese medtech firms are no longer limited to exporting finished hardware; they now align fully with international evaluation standards and export complete domestic regulatory science frameworks. As the multi-center pan-European BRIOLIFE trial advances and accumulates more clinical data, BrioHealth Solutions will deepen its foothold in the global end-stage heart failure market while building a replicable blueprint for other Chinese innovative medical device companies pursuing overseas expansion.